PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: AnaSpec, Inc.

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

AnaSpec Announces Custom Hybridoma Development - Leveraging our world-class peptide synthesis expertise and antibody production experience, AnaSpec, EGT Group is pleased to offer high quality custom monoclonal antibody services to the research community and pharmaceutical industry
AnaSpec Announces Custom Hybridoma Development

 

NewswireToday - /newswire/ - Fremont, CA, United States, 2012/10/08 - Leveraging our world-class peptide synthesis expertise and antibody production experience, AnaSpec, EGT Group is pleased to offer high quality custom monoclonal antibody services to the research community and pharmaceutical industry.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

We have the capabilities to raise monoclonal antibodies to difficult antigens, including peptide sequences that contain post-translational modifications.

• Consultation in peptide antigen design;
• Peptide antigens with post-translational modifications can be made;
• Flexible protocol and schedule based on customer’s needs;
• Immunization time frame of four to eight weeks;
• Up-to-date report and customer validation following each project step;
• Accessible technical support with expertise in antibody production;
• Resources and technical proficiency to work with customer on unconventional projects.

Our routine production of monoclonal antibodies is comprised of three phases (Phase I – III). Customers only pay for each phase that is successfully completed. Phase IV, large-scale production of monoclonal antibodies, is optional and available as a stand-alone purchase. Details of each phase are shown below.

Phase I: Antigen Preparation and Immunization (~8-9 weeks);
• Design and production of synthetic peptide antigens with or without modifications;
• Site-directed conjugation of peptide antigens to carrier proteins (e.g., KLH and BSA) for flexibility in antigen presentation;
• Preparation of peptide and protein antigens with adjuvants for immunization;
• Initial and boost immunizations of at least four animals;
• Serum separation, ELISA testing and customer consultation before proceeding to Phase II.

Phase II: Fusion and Selection of Parental Clones (~3 weeks)
• Splenocytes are harvested for cell fusion from mice with the highest titer;
• Clones of fused cells are expanded and screened by ELISA;
• Supernatants, from up to ten ELISA-positive parental clones, are shipped to customer for further antibody testing in immunoassays;
• The best parental clones (up to three) are chosen for Phase III after customer consultation.

Phase III: Subcloning and selection of Single Clones (~3 weeks)
• Parental clones are sub-cloned by limiting dilution to isolate single clones;
• Isotype determination of single clones – IgG subtype guaranteed single clones are expanded and screened by ELISA;
• Single clones with high specificity (e.g., phospho vs. non-phospho) and antibody titer will be expanded and cryopreserved;
• Three hybridomas, and their supernatants, will be shipped to customer.

Phase IV: Large-Scale Production of Monoclonal Antibodies (optional) (~3-6weeks)
• In vivo ascites or in vitro Bioreactor antibody production is available;
• Purification of monoclonal antibodies by affinity chromatography using Protein G or with the immunizing peptide antigen;
• ELISA and SDS-PAGE are done to validate the purity of the antibody;
• AnaSpec offers a range of production scales with flexible cost adjustment.

In addition to our custom services, AnaSpec, EGT Group offers popular catalog monoclonal antibodies such as the anti-amyloid (1-40) and (1-42) antibodies.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: AnaSpec, Inc.

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


AnaSpec Announces Custom Hybridoma Development

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: Tiffany Kao - AnaSpec.com 
510-791-9560
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any AnaSpec, Inc. securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From AnaSpec, Inc. / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

U.S. FDA Approves New Indication for Ipsen’s Somatuline® Depot (lanreotide) Injection for the Treatment of Carcinoid Syndrome
Genentech Provides Update on First Lampalizumab Phase III Study for Geographic Atrophy, an Advanced Form of Age-Related Macular Degeneration
mProve Health and Greenphire Partner to Deliver a First-of-its-Kind Patient Engagement Solution
FDA Approves Genentech’s Actemra (Tocilizumab) for the Treatment of CAR T Cell-Induced Cytokine Release Syndrome
Greenphire Named to Inc. 5000 for Fifth Consecutive Year
Five Community Health Centers Honored for Innovative Approaches to Medication Therapy Management
FDA Grants Priority Review for Genentech’s Gazyva in Previously Untreated Follicular Lymphoma
ProSci Incorporates Flow Cytometry Screening to Custom Monoclonal Antibody Service
FDA Grants Priority Review to Genentech's Emicizumab for Hemophilia A with Inhibitors
BD Expands Suite of Blood Culture Offerings with New BD BACTEC™ Standard Aerobic & Standard Anaerobic Plastic Bottles
Twist Bioscience Collaborates with Synbio Technologies to Supply Long DNA to Customers
FDA Grants Priority Review and Breakthrough Therapy Designation for Zelboraf (vemurafenib) in Erdheim-Chester Disease with BRAF V600 Mutation
Ipsen Receives Positive CHMP Opinion for Approval of Xermelo® (telotristat Ethyl)
BD Receives FDA 510(k) Clearance for New Immunological Diagnostic System
Positive Phase III Results for Genentech’s Emicizumab in Hemophilia A Published in The New England Journal of Medicine

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  NAKIVO, Inc.

Visit  RightITnow Ltd





 
  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)